AUS
NZ
UK
CA
USA
IND
Motif Bio Plc is a biopharmaceutical company and engaged in the development of novel antibiotics to treat patients with infections caused by multi-drug resistant bacteria. The company develops Iclaprim and has operations in the UK and the US. The group has three drugs in active development and three inactive drugs. The group has patents as an owner of four drugs.
Recent developments
In March 2019, the clinical-stage biopharmaceutical company has issued around 45,000,000 new ordinary shares to new and the existing shareholders for a price of 6p each. It raised around £2.7 mn to support the company with additional working capital.
A couple of weeks ago the biopharmaceutical company did a tie-up with Scottish biotech to grow iclaprim as cystic fibrosis lung infection treatment. The group consider iclaprim antibiotic would do well alongside Lamellar Biomedicalâs LMS-611 and decide to carry one vivo study.
Full Year Results â FY18
The companyâs reported net loss stood at $14.0 mn against the loss of $44.8 mn in FY17 and net loss per share of $0.05 during the period against the per share net loss of $0.19 in 2017.
Research and development expenditure was lowered to $11.0 mn, as compared with $29.5 mn in FY17. Primarily driven a decline in expense for the Iclaprim Phase III clinical trial programme, which stood at $22.1 mn and got completed in 2017 . The company reported general and administrative expenses of $7.6 mn in FY2018 against $8.5 mn reported in FY2017.
At the end of the FY18, Cash and Cash equivalents of the company stood at $12.3 mn, and outstanding ordinary shares stood at 296.7 mn.
Stock Performance
Daily Price Chart (as on May 22, 2019), before the market close. (Source: Thomson Reuters)
At the time of writing (before the market close, at 12:15 PM GMT), the share of LSE: MTFB were hovering in green at GBX 8.09 and added 0.69 points or 9.3 per cent against the yesterday's close. During the past one year, shares have touched a 52w high of GBX 44.90 and a 52w low of GBX 4.69, and at the current market price, as quoted in the price chart, shares were trading around 81.98 per cent below the 52w high price level.
Also, from the simple moving average standpoint, shares were trading substantially below the 200-day simple moving average price, which a bearish technical indicator. The companyâs stock beta was 0.41, reflecting lower volatility as compared to the benchmark index. The outstanding market capitalisation of the company stood at around £24.15 mn.
